ImmunoBiology Limited (ImmBio) Company Profile

12:33 EDT 19th March 2018 | BioPortfolio

Limited [ImmBio] is a biotechnology company specialising in the treatment of infectious diseases and cancer. ImmBio's approach is to apply advances in the emerging science of Immunobiology to the development of treatments for infections diseases and cancer.
Immbio is developing a proprietary vaccine technology based on these advances. The platform technology is called HspC™ vaccination.

HspC™ vaccination is designed to elicit a broad immune response that is specific to the chosen pathogen. HspC™ vaccination thus elicits a more powerful and longer lasting immune response than any alternate treatment regimes. Immbio will initially focus on treatments for infectious diseases (e.g. tuberculosis, influenza and hepatitis).

Dr Colaco set up Immbio in May 1999 to apply the principles of Immunobiology to the treatment of infectious diseases and cancer. In September 1999, ImmBio won a SMART award to begin development of a TB vaccine and this is the initial focus of the company. In 2003 ImmBio raised further funds to complete its TB PoP studies and begin an influenza vaccine programme


Babraham Bioincubator
United Kingdom


Phone: 44 (0) 1223 496116
Fax: 44 (0) 1223 496116

News Articles [34 Associated News Articles listed on BioPortfolio]

YCC launches new Yale Center for Immuno-Oncology

Yale Cancer Center has launched the Yale Center for Immuno-Oncology. The new center will build on YCC's international leadership in immunobiology, cancer immunology, and development of novel cancer im...

Genetic Technologies Limited: Update on Strategic Alliance

MELBOURNE, Australia, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG) (NASDAQ:GENE) (“Company”, “GTG”), wishes to advise that the Company is presently in discussi...

Appointment of Director

Oxford, UK, 1 November 2017: e-Therapeutics plc (AIM: ETX), a company pioneering the use of Network-Driven Drug Discovery (NDD) to create new and better drugs, announces the appointment of Christine...

Genetic Technologies Limited: Project Shivom Strategic Alliance

MELBOURNE, Australia, March 06, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG)  (NASDAQ:GENE) (“Company”, “GTG”) a diversified molecular diagnostics company; provider of...

Telix Pharmaceuticals Limited Lists on the Australian Securities Exchange

MELBOURNE, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the developmen...

Quotient Limited Reports Second Quarter Fiscal 2018 Financial Results

MosaiQ project de-risked, Verification and Validation (“V&V”) “head-to-head” studies confirm targeted concordance levels for all blood grouping assaysEuropean field trials planned to co...

Immutep Limited Announces Milestone Payment From Chinese Partner EOC Pharma

SYDNEY, Australia, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) announced today that it has received a milestone payment from the Company’s Chinese partner for efti...

Quotient Limited to Participate in the Jefferies 2017 London Healthcare Conference

JERSEY, Channel Islands, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Execut...

PubMed Articles [25 Associated PubMed Articles listed on BioPortfolio]

Looking back on the alternative complement pathway.

The alternative pathway of complement originated from the Properdin pathway originally described by the Pillemer laboratory in the 1950s. This work generated great controversy and it took several deca...

Serum interleukin-6 levels are increased in HIV-infected patients that develop autoimmune disease during long-term follow-up.

Elevated IL-6 levels have been associated with both autoimmune diseases and treated HIV-seropositive (HIV(+)) subjects. However, few data on classic and trans-signaling IL-6 in autoimmune thyroid dise...

Glucocorticoid hormone treatment enhances the cytokine production of regulatory T cells by upregulation of Foxp3 expression.

Despite the fact that glucocorticoids (GC) are important therapeutic tools, their effects on regulatory T cells (Treg) are not well defined. The aim of our work was to investigate how GCs influence in...

The Role of MHC-E in T Cell Immunity Is Conserved among Humans, Rhesus Macaques, and Cynomolgus Macaques.

MHC-E is a highly conserved nonclassical MHC class Ib molecule that predominantly binds and presents MHC class Ia leader sequence-derived peptides for NK cell regulation. However, MHC-E also binds pat...

When Immune Cells Turn Bad-Tumor-Associated Microglia/Macrophages in Glioma.

As a substantial part of the brain tumor microenvironment (TME), glioma-associated microglia/macrophages (GAMs) have an emerging role in tumor progression and in controlling anti-tumor immune response...

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

Immunobiology of Cancer

To learn whether or not an Interferon defect in cell signaling, recently discovered in immune cells from melanoma patients as well as breast cancer patients, is common to all cancers.

Immunobiology of Diabetes and Tuberculosis

Despite reports that diabetes mellitus increases the risk of tuberculosis by as much as 11-fold, few studies have focused on the underlying mechanism for this susceptibility. Our ultimate ...

Companies [85 Associated Companies listed on BioPortfolio]

ImmunoBiology Limited (ImmBio)

Limited [ImmBio] is a biotechnology company specialising in the treatment of infectious diseases and cancer. ImmBio's approach is to apply advances in the emerging science of Immunobiology to the deve...

Microsulis Medical Limited

Founded in 1997, Microsulis Medical Limited is a UK-based medical device company that exploits specialist intellectual property in medical microwave design to create therapeutic d...

Maine Biotechnology Services , Inc.

Since 1990, Maine Biotechnology Services, Inc. has offered a comprehensive range of immunochemicals and contract immunobiology manufacturing services. We focus on contract hybridoma and polyclonal ant...

Immunocore Limited

Immunocore Limited is developing innovative biological therapeutics to treat a range of cancers, chronic viral infections and diabetes. Immunocore is a privately owned biotechnology company located ...


More Information about "ImmunoBiology Limited (ImmBio)" on BioPortfolio

We have published hundreds of ImmunoBiology Limited (ImmBio) news stories on BioPortfolio along with dozens of ImmunoBiology Limited (ImmBio) Clinical Trials and PubMed Articles about ImmunoBiology Limited (ImmBio) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ImmunoBiology Limited (ImmBio) Companies in our database. You can also find out about relevant ImmunoBiology Limited (ImmBio) Drugs and Medications on this site too.

Quick Search


Relevant Topics

Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...

Corporate Database Quicklinks

Searches Linking to this Company Record